Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 5,241 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Germ Cell Neoplasms Clear all

Conditions: Melanoma
Interventions: epothilone b; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 6
States / cities: Aurora, Colorado • Tampa, Florida • The Bronx, New York + 3 more

Conditions: Melanoma (Skin)
Interventions: MART-1 antigen, filgrastim, flu matrix peptide p58-66, gp100 antigen, recombinant MAGE-3.1 antigen, tyrosinase peptide, in vitro-treated peripheral blood stem cell transplantation; Biological · Procedure
Lead sponsor: Baylor Health Care System; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2006
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Malignant Melanoma
Interventions: CP-4055, Sorafenib (Nexavar); Drug
Lead sponsor: Clavis Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • San Antonio, Texas

Conditions: Ewing Sarcoma, Ewing Sarcoma of Bone, Ewing Sarcoma of Soft Tissue, Peripheral Primitive Neuroectodermal Tumor, Peripheral Primitive Neuroectodermal Tumor of Bone, Peripheral Primitive Neuroectodermal Tumor of Soft Tissue, High-grade Osteosarcoma
Interventions: FoundationOne Liquid CDx; Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 12 Months to 50 Years
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 15
States / cities: Los Angeles, California • Atlanta, Georgia • Boston, Massachusetts + 9 more

Conditions: Melanoma
Interventions: EF5 Hypoxia; Drug
Lead sponsor: Douglas Tyler; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Melanoma (Skin)
Interventions: aldesleukin; Biological
Lead sponsor: Blumenthal Cancer Center at Carolinas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1995
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Merkel Cell Carcinoma
Interventions: Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Retifanlimab, Tuparstobart, Verzistobart; Procedure · Biological · Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Glioblastoma Multiforme (GBM)
Interventions: HER.CAR CMV-specific CTLs; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Ependymoma, Recurrent Childhood Giant Cell Glioblastoma, Recurrent Childhood Glioblastoma, Recurrent Childhood Gliosarcoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Oligodendroglioma
Interventions: lapatinib ditosylate, therapeutic conventional surgery, laboratory biomarker analysis, pharmacological study, positron emission tomography, magnetic resonance imaging; Drug · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Melanoma
Interventions: autologous tumor cells plus GM-CSF-in Adjuvant; Biological
Lead sponsor: Craig L Slingluff, Jr; Other
Eligibility: 18 Years to 85 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Bone Marrow Suppression, Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ
Interventions: filgrastim, gene therapy, lomustine, procarbazine hydrochloride, vincristine sulfate, in vitro-treated peripheral blood stem cell transplantation; Procedure · Biological · Drug
Lead sponsor: Indiana University; Other
Eligibility: 5 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2011
U.S. locations: 2
States / cities: Indianapolis, Indiana • Boston, Massachusetts

Conditions: Melanoma
Interventions: SB-485232; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Santa Monica, California + 9 more

Conditions: Melanoma
Interventions: Exercise Intervention, Wellness Intervention; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Metastatic Melanoma, Head and Neck Squamous Cell Carcinoma
Interventions: GR-MD-02, Placebo, Pembrolizumab; Drug
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Glioblastoma, Glioma
Interventions: Bevacizumab, Peptide Vaccine, Poly-ICLC as immune adjuvant, Keyhole limpet hemocyanin (KLH); Drug · Biological
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Glioblastoma
Interventions: Radiation Therapy, Temozolomide Oral Product; Radiation · Drug
Lead sponsor: John Flickinger; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Central Nervous System Sarcoma, Ependymoma, Glioma, Malignant Intracranial Germ Cell Tumor, Medulloblastoma, Pineoblastoma, Primary Central Nervous System Neoplasm
Interventions: Placebo Administration, Questionnaire Administration, Wound Dressing Material; Other · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 2 Years to 17 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Carcinoma
Interventions: Capecitabine, Carboplatin, Cisplatin, Etoposide, Laboratory Biomarker Analysis, Temozolomide; Drug · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2029
U.S. locations: 673
States / cities: Kingman, Arizona • Phoenix, Arizona • Fort Smith, Arkansas + 431 more

Conditions: Appendix Adenocarcinoma, Human Papillomavirus-Related Anal Squamous Cell Carcinoma, Human Papillomavirus-Related Cervical Squamous Cell Carcinoma, Human Papillomavirus-Related Squamous Cell Carcinoma of the Penis, Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma, Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Tumor, Recurrent Merkel Cell Carcinoma, Recurrent Nasopharynx Carcinoma, Recurrent Peritoneal Malignant Mesothelioma, Recurrent Pleural Malignant Mesothelioma, Stage III Merkel Cell Carcinoma AJCC v7, Stage III Nasopharyngeal Carcinoma AJCC v7, Stage III Pleural Malignant Mesothelioma AJCC v7, Stage IV Merkel Cell Carcinoma AJCC v7, Stage IV Nasopharyngeal Carcinoma AJCC v7, Stage IV Pleural Malignant Mesothelioma AJCC v7, Stage IVA Nasopharyngeal Carcinoma AJCC v7, Stage IVB Nasopharyngeal Carcinoma AJCC v7, Stage IVC Nasopharyngeal Carcinoma AJCC v7, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
Interventions: Atezolizumab, Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study; Drug · Biological · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Medullary Thyroid Carcinoma, Multiple Endocrine Neoplasia Type 2A, Multiple Endocrine Neoplasia Type 2B
Interventions: Vandetanib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 5 Years to 18 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Melanoma (Skin)
Interventions: aldesleukin, filgrastim, therapeutic tumor infiltrating lymphocytes, cyclophosphamide, fludarabine phosphate, radiation therapy; Biological · Drug · Radiation
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Advanced Solid Tumors
Interventions: BLZ945, PDR001; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 4
States / cities: Boston, Massachusetts • Nashville, Tennessee • Houston, Texas + 1 more

Conditions: Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET Gene Mutation, Metastatic Solid Tumor, Advanced Solid Tumor
Interventions: TPX-0046; Drug
Lead sponsor: Turning Point Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 20
States / cities: La Jolla, California • Orange, California • Aurora, Colorado + 15 more

Conditions: Malignant Gliomas, Oligodendrogliomas, Astrocytomas
Interventions: 3 Tesla scanning; Device
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Search by objective public record fields.

EPO906 Therapy in Patients With Advanced Melanoma

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma

Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD

EF5 in Melanoma Patients

Interleukin-2 in Treating Patients With Metastatic Melanoma

Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma

CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM

Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors

Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma

Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors

Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma

3-month Aerobic and Resistance Exercise Intervention for Individuals Diagnosed With Melanoma

GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients

A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma

Short Course Chemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma

StrataXRT in Preventing Radiation Dermatitis in Pediatric Patients Undergoing Radiation Therapy to the Brain or Spinal Cord

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer

Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma

A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors

Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

Clinical Development of Cancer-Specific MRS Biomarkers in Malignant Gliomas